.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Two-year results from the phase 3 YOSEMITE and RHINE trials evaluated faricimab delivered through a personalized treat-and-extend approach in diabetic macular edema (DME). Visual acuity gains were maintained through year two and were noninferior to aflibercept dosed every eight weeks. An important feature was durability: many patients receiving faricimab in the treat-and-extend arms could be extended to 12- or 16-week intervals, reducing the number of injections required over the study period. Anatomic improvements were also sustained, with reductions in central subfield thickness and improved fluid control. For retina specialists, the study reinforces the value of treatment interval personalization. Rather than treating every patient at a fixed frequency, clinicians can adjust dosing according to visual and anatomic response while preserving meaningful gains. This approach may reduce treatment burden for patients who respond well, especially in chronic diseases such as DME where repeated intravitreal injections can become a major barrier to long-term adherence. The study also supports the concept that durability is now a central efficacy endpoint alongside visual acuity and OCT anatomy.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Two-year results from the phase 3 YOSEMITE and RHINE trials evaluated faricimab delivered through a personalized treat-and-extend approach in diabetic macular edema (DME). Visual acuity gains were maintained through year two and were noninferior to aflibercept dosed every eight weeks. An important feature was durability: many patients receiving faricimab in the treat-and-extend arms could be extended to 12- or 16-week intervals, reducing the number of injections required over the study period. Anatomic improvements were also sustained, with reductions in central subfield thickness and improved fluid control. For retina specialists, the study reinforces the value of treatment interval personalization. Rather than treating every patient at a fixed frequency, clinicians can adjust dosing according to visual and anatomic response while preserving meaningful gains. This approach may reduce treatment burden for patients who respond well, especially in chronic diseases such as DME where repeated intravitreal injections can become a major barrier to long-term adherence. The study also supports the concept that durability is now a central efficacy endpoint alongside visual acuity and OCT anatomy.
Today
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
6 days back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back
